The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 …
A Zereshkian, JV Leyton, Z Cai, D Bergstrom… - Nuclear medicine and …, 2014 - Elsevier
Abstract Introduction Leukemia stem cells (LSCs) are believed to be responsible for initiating
and propagating acute myeloid leukemia (AML) and for causing relapse after treatment.
Radioimmunotherapy (RIT) targeting these cells may improve the treatment of AML, but is
limited by the low density of target epitopes. Our objective was to study a human
polynucleotide kinase/phosphatase (hPNKP) inhibitor that interferes with DNA repair as a
radiosensitizer for the Auger electron RIT agent, 111 In-NLS-7G3, which recognizes the …
and propagating acute myeloid leukemia (AML) and for causing relapse after treatment.
Radioimmunotherapy (RIT) targeting these cells may improve the treatment of AML, but is
limited by the low density of target epitopes. Our objective was to study a human
polynucleotide kinase/phosphatase (hPNKP) inhibitor that interferes with DNA repair as a
radiosensitizer for the Auger electron RIT agent, 111 In-NLS-7G3, which recognizes the …